Press releases
ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors
Enara Bio, ROME Therapeutics and Nucleome Therapeutics to Host 2nd Annual Dark Genome Symposium
ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer
ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
News and events
Enara Bio, ROME Therapeutics and Nucleome Therapeutics Host 2nd Annual Dark Genome Symposium
Scientific presentations
Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses | ACR Convergence 2023
Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription | EMBO Workshop: The Mobile Genome